In our study, although patients with LRP1B mutation had higher bTMB, CRP, PD-L1 positive rate, and larger tumor size, the association of LRP1B mutation with improved outcomes to ICI plus chemotherapy remained consistent after controlling for these factors. This evidence concerns the gene CD274 and neoplasm.